HIGHLIGHTS
SUMMARY
In two studies by Robak et_al, bortezomib replaced vincristine in the R-CHOP regimen as frontline therapy for MCL in patients who were not eligible for stem_cell therapy. In the study of Williams et_al, similar toxicities occurred but at a lower frequency than in the cohort. Considering renal toxicity, seven patients in the bortezomib -BeEAM cohort (64% of all patients) had a decline in renal function, with five of them (45% of all patients) developing acute renal failure. In the study of Hueso et_al, similar rates of acute renal failure were described as in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.